Risk of Cancer in Patients with Bile Acid Diarrhoea: a Danish Nationwide Matched Cohort Study

Overview

Journal BMJ Open Gastroenterol

Specialty Gastroenterology

Date 2024 Apr 30

PMID 38688717

Authors

Nynne Nyboe Andersen

Signe Wildt

Aske Thorn Iversen

Gry Poulsen

Tine Jess

Lars Kristian Munck

Christian Borup

Affiliations

Soon will be listed here.

Abstract

Objective: Bile acid diarrhoea is a common cause of chronic diarrhoea. Increased levels of potentially carcinogenic bile acids in faeces, theoretically, may increase the risk of colorectal cancer in particular, but the long-term disease course is unknown. We aimed to investigate the overall and site-specific cancer risk in bile acid diarrhoea.

Design: Adult patients with bile acid diarrhoea were identified using nationwide Danish registries from 2003 to 2020 by a diagnostic gold-standard 75-selenium tauroselcholic acid procedure followed within 6 months by sequestrant prescription. The risk of overall and site-specific cancers in cases with bile acid diarrhoea was compared with sex, age and comorbidity-adjusted matched controls. A competing risk model estimated cumulative incidence functions and cause-specific HRs.

Results: We identified 2260 patients with bile acid diarrhoea with a mean follow-up of 5.5 years (SD 4.2). The overall cancer risk was increased by an HR of 1.32 (95% CI 1.12 to 1.54). The risk of site-specific cancer was increased in 3 of 10 cancer groups: haematological, HR 2.41 (1.36 to 4.02); skin, HR 1.33 (1.01 to 1.71); and male genital cancers, HR 1.85 (1.11 to 2.92). No increased risk of colorectal cancer was detected in patients with bile acid diarrhoea, HR 0.73 (0.34 to 1.63).

Conclusions: Bile acid diarrhoea was associated with an increased overall risk of cancer, especially haematological cancers, but the risk of colorectal cancer was not increased. The lack of a diagnostic code for bile acid diarrhoea and potential residual confounding are limitations, and the findings should be replicated in other cohorts.

References

Keum N, Lee D, Greenwood D, Manson J, Giovannucci E . Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol. 2019; 30(5):733-743. PMC: 6821324. DOI: 10.1093/annonc/mdz059. View

Jeffery I, Das A, OHerlihy E, Coughlan S, Cisek K, Moore M . Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. Gastroenterology. 2019; 158(4):1016-1028.e8. DOI: 10.1053/j.gastro.2019.11.301. View

Visekruna A, Luu M . The Role of Short-Chain Fatty Acids and Bile Acids in Intestinal and Liver Function, Inflammation, and Carcinogenesis. Front Cell Dev Biol. 2021; 9:703218. PMC: 8352571. DOI: 10.3389/fcell.2021.703218. View

Andersen T, Madsen M, Jorgensen J, Mellemkjoer L, Olsen J . The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999; 46(3):263-8. View

Wedlake L, AHern R, Russell D, Thomas K, Walters J, Andreyev H . Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009; 30(7):707-17. DOI: 10.1111/j.1365-2036.2009.04081.x. View

Rezen T, Rozman D, Kovacs T, Kovacs P, Sipos A, Bai P . The role of bile acids in carcinogenesis. Cell Mol Life Sci. 2022; 79(5):243. PMC: 9013344. DOI: 10.1007/s00018-022-04278-2. View

Karhus M, Bronden A, Forman J, Haaber A, Knudsen E, Langholz E . Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial. Lancet Gastroenterol Hepatol. 2022; 7(10):922-931. DOI: 10.1016/S2468-1253(22)00198-4. View

Migliaccio S, Di Nisio A, Magno S, Romano F, Barrea L, Colao A . Vitamin D deficiency: a potential risk factor for cancer in obesity?. Int J Obes (Lond). 2022; 46(4):707-717. DOI: 10.1038/s41366-021-01045-4. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

10.

Camilleri M . Bile acid detergency: permeability, inflammation, and effects of sulfation. Am J Physiol Gastrointest Liver Physiol. 2022; 322(5):G480-G488. PMC: 8993532. DOI: 10.1152/ajpgi.00011.2022. View

11.

Jia W, Xie G, Jia W . Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2017; 15(2):111-128. PMC: 5899973. DOI: 10.1038/nrgastro.2017.119. View

12.

Mu L, Li W, Ren W, Hu D, Song Y . The association between cholecystectomy and the risk of colorectal cancer: an updated systematic review and meta-analysis of cohort studies. Transl Cancer Res. 2023; 12(6):1452-1465. PMC: 10331452. DOI: 10.21037/tcr-22-2049. View

13.

Appleby R, Moghul I, Khan S, Yee M, Manousou P, Neal T . Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. PLoS One. 2019; 14(1):e0211348. PMC: 6347262. DOI: 10.1371/journal.pone.0211348. View

14.

Murray I, Murray L, Woolson K, Sherfi H, Dixon I, Palmer J . Incidence and predictive factors for positive SeHCAT test: improving the diagnosis of bile acid diarrhoea. Scand J Gastroenterol. 2017; 52(6-7):698-703. DOI: 10.1080/00365521.2017.1298153. View

15.

Gracie D, Kane J, Mumtaz S, Scarsbrook A, Chowdhury F, Ford A . Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil. 2012; 24(11):983-e538. DOI: 10.1111/j.1365-2982.2012.01953.x. View

16.

Walters J, Tasleem A, Omer O, Brydon W, Dew T, le Roux C . A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009; 7(11):1189-94. DOI: 10.1016/j.cgh.2009.04.024. View

17.

Camilleri M . Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver. 2015; 9(3):332-9. PMC: 4413966. DOI: 10.5009/gnl14397. View

18.

Ridlon J, Kang D, Hylemon P, Bajaj J . Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014; 30(3):332-8. PMC: 4215539. DOI: 10.1097/MOG.0000000000000057. View

19.

Reddy B . Role of bile metabolites in colon carcinogenesis. Animal models. Cancer. 1975; 36(6 Suppl):2401-6. DOI: 10.1002/1097-0142(197512)36:6<2401::aid-cncr2820360619>3.0.co;2-o. View

20.

Takeuchi M, Tsunemi K, Iwata M, Kaga M, Shimpo K, Takahashi N . [Carcinogenicity study of cholestyramine in mice]. J Toxicol Sci. 1982; 7 Suppl 1:35-55. DOI: 10.2131/jts.7.supplementi_35. View